What You Should Know
- The Deal: Solace Health has raised a $130M Series C led by IVP with participation from Menlo Ventures, SignalFire, propelling the company to a valuation of over $1 billion. This “unicorn” status reflects a massive bet that healthcare advocacy is becoming essential infrastructure.
- The Mission: Solace acts as a “human layer” on top of the fragmented healthcare system. It connects patients with over 2,000 trained advocates (often nurses) to manage logistics, appointments, and insurance hurdles—services that 20,000 patients now use monthly.
- The Origin: The company was founded after CEO Jeremy Gurewitz watched his mother—an accomplished radiologist—struggle to navigate her own pancreatic cancer diagnosis. The realization was stark: if a doctor can’t navigate the system, the system is broken for everyone.
The “Doctor Who Couldn’t Navigate”
The origin story of Solace cuts to the heart of the problem. Gurewitz founded the company with CPO Sara Sargent in 2022 after a personal crisis. His mother, a radiologist with decades of medical expertise, found herself unable to navigate her own pancreatic cancer diagnosis.
It exposed a terrifying truth: medical literacy isn’t enough. The friction of the administrative system is so high that even insiders get stuck. Solace was built to close that gap. It creates a dedicated role—the Healthcare Advocate—to intervene between diagnosis and treatment.
Traction/Market Footprint
Today, Solace serves more than 20,000 patients monthly through its HIPAA-compliant platform, connecting them with expert advocates via text, phone, and video. With 10x year-over-year growth and IVP’s backing, the company is poised to scale its model nationwide and shorten time-to-diagnosis, reduce avoidable hospitalizations, and materially improve patient outcomes.
“The healthcare system has normalized leaving patients to figure things out themselves in their vulnerable moments,” said Jeremy Gurewitz, CEO and co-founder of Solace. “That failure is costly, dangerous, and preventable.”
